Mohan Teena, Verma Priyanka, Rao D N
Department of Biochemistry, All India Institute of Medical Sciences (A.I.I.M.S.), Ansari Nagar, New Delhi 110029, India.
Department of Biochemistry, All India Institute of Medical Sciences (A.I.I.M.S.), Ansari Nagar, New Delhi 110029, India.
Immunobiology. 2014 Apr;219(4):292-301. doi: 10.1016/j.imbio.2013.11.001. Epub 2013 Nov 17.
The MPER of gp41 of HIV-1 has received great attention and is widely recognized as a promising target for the development of AIDS vaccine. We investigated the ability of trirepeat of ELDKWA sequence of gp41 antigen with defensins in liposome using multiple-shot immunization strategy in the mice model. The designed was used to enhance the immunogenicity and exposure of MPER in its native conformation for the induction of MPER-specific HIV-1 neutralizing antibodies. To characterize, we estimated the antibody levels (IgG/IgA) in serum as well as in lung, intestinal, vaginal and rectal washes till day 120 in outbred and inbred (H-2(b) and H-2(d)) mice using liposome as delivery vehicle. The representative sera and washes were also tested for in vitro neutralization with CCR5-tropic Indian HIV-1 primary isolates. We observed that the modified HIV antigen containing trirepeat of ELDKWA with defensins was showing significantly (p<0.001) higher IgG/IgA antibody titre (102,400-204,800) in sera as well as in different mucosal washes (1600-6400) than standard HIV-1 antigen. Furthermore, sera from the modified HIV-1 antigen with defensins found to exhibit higher neutralizing activities (ranging from 59.3% to 84.6%) than the standard HIV-1 antigen. These results show that the induction of MPER-specific HIV-1 neutralizing antibodies could be achieved through a rationally designed vaccine strategy.
HIV-1的gp41膜近端外部区域(MPER)备受关注,被广泛认为是开发艾滋病疫苗的一个有前景的靶点。我们在小鼠模型中采用多次免疫策略,研究了gp41抗原的ELDKWA序列三重复体与防御素在脂质体中的作用。该设计用于增强MPER以其天然构象的免疫原性和暴露程度,从而诱导产生MPER特异性的HIV-1中和抗体。为进行表征,我们以脂质体作为递送载体,在远交和近交(H-2(b)和H-2(d))小鼠中,评估了直至第120天血清以及肺、肠道、阴道和直肠灌洗液中的抗体水平(IgG/IgA)。还使用CCR5嗜性的印度HIV-1原代分离株对代表性血清和灌洗液进行了体外中和试验。我们观察到,含有ELDKWA三重复体与防御素的修饰HIV抗原在血清以及不同黏膜灌洗液中显示出显著更高(p<0.001)的IgG/IgA抗体滴度(102,400 - 204,800),高于标准HIV-1抗原。此外,含有防御素的修饰HIV-1抗原的血清显示出比标准HIV-1抗原更高的中和活性(范围为59.3%至84.6%)。这些结果表明,通过合理设计的疫苗策略可以实现MPER特异性HIV-1中和抗体的诱导。